NIH analysis of 2021 cancer incidence data finds that missed diagnoses were not accounted for What: Cancer incidence trends in 2021 larg...
The European Society for Medical Oncology (ESMO) 2024 Congress, held from September 13 to 17 in Barcelona, brought together global oncology experts to un...
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...
Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, announces that the U...
– Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromata...
BeiGene, a global oncology company, announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA® (tislelizumab) as monotherapy for t...
Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion coho...
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCL...
GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bi...
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians...
Guardant Health Japan Corp. (HQ: Minato-ku, Tokyo/ Representative Director: Mika Takaki), a leading precision oncology company, announced that the M...
LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer In...
-Curebound, a philanthropic organization that raises and invests strategic funding for cancer research, is announcing important updates on its grant reci...
Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy(ipilimumab) compared to in...
© 2025 Biopharma Boardroom. All Rights Reserved.
